Osteo Arthritis Therapeutics - Pipeline Analysis 2018

Global Osteoarthritis Therapeutics Pipeline Analysis 2018

Chhattisgarh, INDIA

Verna, Goa, India, April 26, 2018 (GLOBE NEWSWIRE) -- GervanoRA Data Services added updated “Osteoarthritis Therapeutics – Pipeline Analysis 2018” to the report store and it is now available on discounted price. Osteoarthritis (OA) has been defined as “a progressive disease of synovial joint that failed repair of joint damage which results from stresses, may be initiated by an abnormality in any of the synovial joint tissues, including articular cartilage, subchondral bone, ligaments, menisci (when present), periarticular muscles, peripheral nerves, or synovium” . OA can affects single and/or multiple peripheral joints like knee, hip, and hand. The Osteoarthritis pipeline analysis – 2018 report provides a snapshot of the global pipeline therapeutics’ landscape of Osteoarthritis and built to provide strategically important competitor information, analytics, and insights to formulate effective counter research and development strategies. Report concentrated more on emerging companies with potentially strong product portfolio and recognized significant and varied types of therapeutics under development. And report clearly explains the opportunities of co-development, partnering and investments.

Report helps emerging companies to understand the strong competitor strategies through its key company profiles and SWOT analysis. Elaborated report information assist clients in understanding the current scenarios in drug development and help in develop and design pipeline based in-licensing and out-licensing strategies. Report explained the role of universities and institutes in osteoarthritis drug development without ignoring the discontinued and dormant projects. Following segments helps clients to understand this report with more clarity.

Report Highlights:

There are total 167 molecules in pipeline (Company Molecules 97, University Molecules 41 and Institute Molecules 29) in different phases of development. Among these 167 molecules, 2 drugs are expected to approve in 2019, 2 in 2021 and 11 in 2022.

Report provides comprehensive information on the therapeutics under development for Osteoarthritis with analysis by stage of development, drug class, mechanism of action (MoA), route of administration (RoA), geography and developers (Companies, Universities and Institutes).

Report Coverage:

  • Key Pipeline Events
  • Drug Pipeline Analysis by Stage of Development, Geography, RoA, MoA, Drug Class, and Drug developments by companies, universities and Institutes.
  • Disease overview
  • Osteoarthritis Related Deals Activities
  • Total Drug Approvals for the Treatment of Osteoarthritis (From 2010)
  • Patent Analysis of Approved Drugs and Pipeline Drugs
  • Estimated Drug Approval Timelines for all Pipeline Drugs
  • Clinical Trials Summary
  • Terminated and Discontinued Drugs Projects
  • Current and Future Competitive Landscape of Companies
  • Key Companies with Drug Profiles and Drug Milestones
  • Key Companies SWOT Analysis
  • Emerging Companies with Drug Profiles and Drug Milestones
  • Universities with Osteoarthritis Drugs in Pipeline
  • Institutes with Osteoarthritis Drugs in Pipeline

For more details on report structure and TOC, Please avail our Sample report by sending a mail to sales@gervanora.com and provide your details like your name, designation, company name etc.

About GervanoRA

GervanoRA Data Services LLP is a premier provider of syndicated research reports, custom research reports and consulting services, based in Goa, India. GDS aims to deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, aerial views of the competitive framework, and future market trends.

At GervanoRA Data Services, we're playing our part to help clients stay ahead of the curve. We collaboratively work with a wide range of organizations (KOLs) to garner valuable key insights.

For more details, please visit our website: www.gervanora.com

Connect with us on LinkedIn @ https://in.linkedin.com/company/gervanora-data-services-llp


Contact Data